

June 26, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,


Sub : Disclosure of Related Party Transactions for the half year ended 31st March 2019.
Ref : Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 31st March 2019.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



B Adi Reddy
Company Secretary

Encl: as above.



AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithriviher, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2019

(All amounts are in Indian Rupees in millions)

i) Names of related parties and description of relationship

a) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)
 Eugia Pharma Specialities Limited, India
 Tergene Biotech Private Limited, India
 Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics Limited, India)
 Purple Bellflower (Pty)Ltd, South Africa (w.e.f. 23 August 2018) (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)

b) Enterprises over which key management personnel or their relatives exercise significant influence

Pravesha Industries Private Limited, India
 Sri Sai Packaging, India (Partnership firm)
 Trident Chemphar Limited, India
 Auropro Soft Systems Private Limited, India
 Axis Clinicals Limited, India
 Pranit Projects Private Limited, India
 Pranit Packaging Private Limited, India
 SGD Pharma India Limited (formerly Cogent Glass Limited), India
 Orem Access Bio Inc, India
 Veritaz Healthcare Limited, India
 Alex Merchant PTE. LTD, Singapore
 Trident Petrochemicals DMCC, Dubai
 Axis Clinicals LLC, USA
 Alex Merchant DMCC, Dubai
 Crest Cellulose Private Limited, India
 East Pharma Technologies, India (Partnership firm)
 Axis Clinicals Latina SA DE CV, Mexico
 Gelcaps Industries, India
 Aurobindo Foundation, India

c) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director
 Dr. M. Sivakumaran, Whole-time Director
 Mr. M. Madan Mohan Reddy, Whole-time Director
 Mr. P. Sarath Chandra Reddy, Whole-time Director
 Mr. N. Govindarajan, Managing Director
 Mr. Santhanam Subramanian, Chief Financial Officer
 Mr. B. Adi Reddy, Company Secretary
 Mr. K. Ragunathan, Non-executive Chairman and Independent Director
 Mr. M. Sitarama Murty, Independent Director
 Dr. (Mrs.) Avnit Bimal Singh, Independent Director
 Mr.P.Venkata Ramprasad Reddy, Non Executive promoter director
 Mrs.Savitha Mahajan, Independent Director

d) Relatives to key managerial personnel

Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)

ii) Transactions with related parties

a. Transactions with joint ventures

	Half Year ended 31 March 2019
Raidurgam Developers Limited	
Investment in optionally convertible debentures	136.4
Novagen Pharma (Pty) Limited, South Africa	
Sale of products	118.4
Eugia Pharma Specialities Ltd, India	
Sale of products	40.0
Purchases	0.1
Purchase of property, plant and equipment	0.4
Tergene Biotech Pvt. Ltd, India	
Investment in 10.5% Cumulative Redeemable Preference shares	32.5



Aurobindo Pharma Limited

Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2019

(All amounts are in Indian Rupees in millions)

b. Transactions with enterprises over which key management personnel or their relatives exercise significant influence

**Half Year ended
31 March 2019**

Pravesha Industries Private Limited, India	
Sale of products	0.1
Purchases	1,544.8
Sri Sai Packaging, India	
Sale of products	0.2
Purchases	119.4
Axis Clinicals Limited, India	
Purchase of services	561.4
Purchase of Fixed assets	57.2
Axis Clinicals LLC, USA	
Purchase of services	0.7
Purchase of Fixed Assets	180.6
Trident Chemphar Limited, India	
Purchases	758.9
Purchase of services	82.5
Pranit Packaging Private Limited, India	
Purchases	104.7
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Purchases	565.0
Orem Access Bio Inc, India	
Purchases	144.5
Veritaz Healthcare Limited, India	
Sale of products	99.4
Rent received	0.1
Alex Merchants DMCC, Dubai	
Miscellaneous receipts	0.4
Crest Cellulose Private limited, India	
Purchases	245.0
East Pharma Technologies, India	
Purchases	34.6
Gelecaps Industries, India	
Purchases	193.4
Aurobindo Foundation, India	
- Contribution towards CSR activities	266.0

c. Transactions with key managerial personnel or their relatives

**Half Year ended
31 March 2019**

Mr. K Nityananda Reddy	
Managerial remuneration	8.3
Rent expense	1.3
Dr. M Sivakumaran	
Managerial remuneration	8.3
Mr. M Madan Mohan Reddy	
Managerial remuneration	14.6
Mr. P Sarath Chandra Reddy	
Managerial remuneration	4.7
Mr. Vishnu M Sriram	
Remuneration	3.0
Mr.N Govindarajan	
Managerial Remuneration	125.3
Mr.Santhanam Subramanian	
Remuneration	12.5
Mr.B. Adl Reddy	
Remuneration	2.0
Mr. P.Venkata Ramaprasad Reddy	
Director sitting fees	0.3
Mr. K.Ragunathan, Non-executive Chairman and Independent Director	
Director sitting fees	0.7
Mr. M. Sitarama Murty, Independent Director	
Director sitting fees	0.6
Mrs.Avni Bimal Singh, Independent Director	
Director sitting fees	0.6
Mrs.Savitha Mahajan, Independent Director	
Director sitting fees	0.5

Note:

Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.



Aurobindo Pharma Limited
Disclosure of related party transactions on a consolidated basis for the half year ended 31 March 2019
 (All amounts are in Indian Rupees in millions)

iii) Closing balances of related parties

a. Balances with Joint ventures at the year end

	As at 31 March 2019
Novagen Pharma (Pty) Limited, South Africa	
Balance receivable	101.1
Raidurgam Developers Limited, India	
Balance receivable	8.2
Eugia Pharma Specialities Limited, India	
Balance receivable	39.6

b. Balances with enterprises over which key management personnel or their relatives exercise significant influence at the year end.

	As at 31 March 2019
Pravesha Industries Private Limited, India	
Balance payable	678.7
Sri Sai Packaging, India	
Balance payable	31.7
Axis Clinicals Limited, India	
Balance payable	0.2
Trident Chemphar Limited, India	
Balance receivable	29.3
Balance payable	1.8
Pranit Packaging Private Limited, India	
Balance receivable	0.8
Balance payable	19.0
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Balance payable	236.7
Veritaz Healthcare Limited, India	
Balance receivable	85.8
Orem Access Blo Inc, India	
Balance payable	45.0
Crest Cellulose Private Limited, India	
Balance payable	68.6
East Pharma Technologies, India	
Balance payable	12.5
Gelcaps Industries, India	
Balance receivable	1.7
Balance payable	55.0

c. Balances with with key managerial personnel at the year end

	As at 31 March 2019
Mr.N Govindarajan	
Balance payable	100.0
Mr. K Nityananda Reddy	
Balance payable	0.2

